Waters Corporation and Labcorp Announce Partnership for HPV Screening

Waters Corporation and Labcorp have formed a strategic partnership to enhance cervical cancer screening by introducing the FDA-approved BD Onclarity HPV Assay across Labcorp's national network, starting in late 2026. This collaboration utilizes Waters' diagnostic capabilities following its recent acquisition of specific diagnostic assets, aiming to improve personalized risk assessment and screening options. The initiative is designed to align with ASCCP guidelines and increase access for underserved populations.